What is the 13F Pro Quality Score for SEPN?

13F Pro ranks Septerna, Inc. (SEPN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SEPN's current score at https://13fpro.ai/research/SEPN (free sign-up required for the full ranking).

Which hedge funds own the most SEPN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SEPN include RA CAPITAL MANAGEMENT, L.P., TRV GP V,, DRIEHAUS CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/SEPN as soon as new 13F filings post.

Where does 13F Pro source SEPN data?

All Septerna, Inc. fundamentals and ownership data come directly from SEC EDGAR. Septerna, Inc. files with the SEC under CIK 1984086. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SEPN in?

Septerna, Inc. (SEPN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SEPN research updated on 13F Pro?

SEPN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Septerna, Inc.(SEPN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1984086 SEPN stock profile & AI dashboard →

13F Pro Quality Score

44.6/100

Rank #1,764 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

95.9/100

Profitability

7.5/100

Balance Sheet

19.9/100

Earnings Quality

30.0/100

Free Cash Flow

97.2/100

Institutional Flow

55.7/100

Revenue Scale

10.6/100

Dilution Risk

10.0/100

SEPN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Septerna, Inc. (SEPN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SEPN at 44.6/100 on a 32-signal composite quality model, placing it at rank #1,764 of 2,879 stocks — the bottom half of the AI-ranked universe. SEPN scores in the top quartile across free cash flow (97.2), revenue growth (95.9). Areas of concern include profitability (7.5) and revenue scale (10.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Septerna, Inc. reports quarterly revenue of $26.5M, net income of $-8.6M, free cash flow of $-26.5M. Top institutional holders of SEPN by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., TRV GP V,, DRIEHAUS CAPITAL MANAGEMENT, based on the most recent SEC filings. SEPN trades on the Nasdaq exchange and files with the SEC under CIK 1984086. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SEPN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Septerna, Inc. directly from SEC EDGAR. Septerna, Inc.'s 13F Pro composite quality score has ranged between 5 and 45 since 2025, currently 44.6 — a stable long-term trajectory across 12 quarterly and live scoring snapshots.

✦

Fun facts about Septerna, Inc.

Quirks, history, and lore behind SEPN — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in South San Francisco, the biotech capital of the world.
2
The Numbers
A pre-revenue startup with no approved drugs yet — its balance sheet is essentially cash runway and R&D spend, typical of early-stage biotech IPOs.
3
The History
Founded in the early 2020s and went public relatively recently, raising capital to pursue a target class that dominated drug discovery conversations for decades but remained stubbornly hard to crack.
4
The Secret
The company is laser-focused on G protein-coupled receptors (GPCRs) — a massive and historically undruggable family of proteins involved in nearly every disease area imaginable.
5
The Lore
GPCRs already account for roughly a third of all approved drugs, yet most of the family remains untouched — this company's whole bet is that new structural biology tools finally make the rest accessible.
6
The Giveaway
Its name is a nod to the word "septet" — a wink at the seven transmembrane helices that define every GPCR on earth. Seven helices, one obsession.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$26.5M

Net Income

Q1 2026

$-8.6M

Free Cash Flow

Q1 2026

$-26.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+4174.5% YoY

$46.0MFY 2025

FY23 $151.0KFY24 $1.1MFY25 $46.0M

Net Income

+31.9% YoY

$-48.9MFY 2025

FY23 $4.2MFY24 $-71.8MFY25 $-48.9M

Operating Income

+15.5% YoY

$-68.3MFY 2025

FY23 $2.1MFY24 $-80.8MFY25 $-68.3M

EPS (Diluted)

+84.8% YoY

$-1.10FY 2025

FY23 $0.02FY24 $-7.26FY25 $-1.10

Total Assets

+30.6% YoY

$596.2MFY 2025

FY23 $130.9MFY24 $456.6MFY25 $596.2M

Op. Cash Flow

+263.3% YoY

$110.2MFY 2025

FY23 $-38.7MFY24 $-67.5MFY25 $110.2M

Metric	FY 2025	FY 2024	FY 2023
Revenue	$46.0M +4174.5%	$1.1M +611.9%	$151.0K
Net Income	$-48.9M +31.9%	$-71.8M -1817.7%	$4.2M
Operating Income	$-68.3M +15.5%	$-80.8M -3995.1%	$2.1M
EPS (Diluted)	$-1.10 +84.8%	$-7.26 -35172.5%	$0.02
Total Assets	$596.2M +30.6%	$456.6M +248.9%	$130.9M
Operating Cash Flow	$110.2M +263.3%	$-67.5M -74.2%	$-38.7M

AI Insight: SEPN Ratio Trends

Septerna remains deeply unprofitable with no debt leverage, and Q3 2025's anomalous positive margins appear to be a one-off, not a trend reversal.

• ROE deteriorated from -19.7% in Q4 2024 to -26.3% in Q2 2025, reflecting accelerating cash burn before the Q3 2025 outlier.

• Q3 2025 showed a brief positive spike — OpMargin 12.2%, NPM 38.0%, ROIC 2.7% — but Q4 2025 reversed sharply to -66.4% OpMargin.

• Q1 2026 OpMargin improved modestly to -50.1% from -66.4% in Q4 2025, but remains deeply negative on a TTM basis at -77.1%.

⚠ Q3 2025's positive NPM of 38.0% looks like a one-time item; confirming its nature is critical to assessing true earnings trajectory.

⚠ ROIC has ranged from -14.1% to -30.7% across recent quarters — sustained capital destruction with no clear path to breakeven visible.

⚠ D/E data is entirely absent; without leverage visibility, balance sheet runway and dilution risk remain unquantifiable from this dataset.

Get alerted when SEPN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Septerna, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SEPN

RA CAPITAL MANAGEMENT, L.P.
$168.1M6,995,858 sh
TRV GP V, LLC
$149.4M6,215,591 sh
DRIEHAUS CAPITAL MANAGEMENT LLC
$105.6M4,395,572 sh
TRV GP VI, LLC
$101.2M4,211,659 sh
Samsara BioCapital, LLC
$75.7M3,149,128 sh
GOLDMAN SACHS GROUP INC
$69.8M2,906,427 sh
Siren, L.L.C.
$48.1M2,000,000 sh
BlackRock, Inc.
$43.8M1,822,174 sh
BVF INC/IL
$32.5M1,353,249 sh
Avoro Capital Advisors LLC
$32.1M1,337,500 sh

Fund	Value	Shares
RA CAPITAL MANAGEMENT, L.P.	$168.1M	6,995,858
TRV GP V, LLC	$149.4M	6,215,591
DRIEHAUS CAPITAL MANAGEMENT LLC	$105.6M	4,395,572
TRV GP VI, LLC	$101.2M	4,211,659
Samsara BioCapital, LLC	$75.7M	3,149,128
GOLDMAN SACHS GROUP INC	$69.8M	2,906,427
Siren, L.L.C.	$48.1M	2,000,000
BlackRock, Inc.	$43.8M	1,822,174
BVF INC/IL	$32.5M	1,353,249
Avoro Capital Advisors LLC	$32.1M	1,337,500

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SEPN on your watchlist

Track score changes the day Septerna, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SEPN a good stock to buy?

13F Pro's AI-powered analysis of Septerna, Inc. (SEPN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SEPN are available on the SEPN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SEPN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SEPN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Septerna, Inc.'s investment landscape.